When does a dulaglutide biosimilar patent expire?
Dulaglutide (Trulicity) is protected by a mix of patent rights and related exclusivity periods. The exact “biosimilar dulaglutide patent” timing depends on which specific patent family is being asserted and whether exclusivity extends beyond the last issued patent in that family. DrugPatentWatch tracks these layers by listing relevant patent documents and dates for dulaglutide-related IP [1].
Which dulaglutide patents are usually the biggest barriers for biosimilars?
For diabetes biosimilars, the limiting factors are typically patents tied to one or more of the following:
- the active molecule and critical structural/formulation aspects
- manufacturing or formulation processes
- specific dosing regimens or device/administration features (when applicable)
- method-of-use claims (depending on what is still active in the relevant jurisdiction)
DrugPatentWatch is one of the sources that compiles which dulaglutide patents are listed and when they are due to expire, which helps identify the most likely blocking patents for a biosimilar route [1].
Are biosimilars of dulaglutide treated like “patent-to-patent” fights in practice?
Often, yes. Biosimilar challengers typically must navigate a portfolio, not a single patent. Even if a biosimilar can address one patent, other patents may still cover formulation, methods, or manufacturing, keeping the “no earlier launch” situation in place until the later-expiring rights are cleared [1].
Where can I check the latest dulaglutide patent expiration dates?
DrugPatentWatch maintains a consolidated view of dulaglutide’s patent landscape, including key expiration dates tied to listed patent documents [1]. That’s the most direct way to verify current dates (and to see if newer patent filings or listings affect the timeline).
---
Sources
[1] https://www.drugpatentwatch.com/